x

FROM THE HEART

Our passion for innovation

Ncardia believes that stem cell technology fast-tracks the delivery of better medicines to patients by improving the drug discovery process. We develop, produce and commercialize highly-predictive human cellular (disease) assay systems for safety and efficacy testing aiming to accelerate and improve drug candidate selection, reduce costs and ultimately increase drug discovery and development efficiency.

OUR PRODUCTS

hiPSC-derived Cardiac and Neural products

The cardiac product portfolio encompasses a broad panel of hiPSC-derived Cardiomyocytes (Pluricyte®, Cor.4U® and vCor.4U®) as well as cardiac fibroblasts (FibroCor.4U®). In addition, the company delivers the CardioPlateTM product line of quality controlled, ready-to-use assay plates. The neural cell product portfolio contains the pan-neuronal cells CNS.4U®, the peripheral neurons Peri.4U®, and astrocytes Astro.4U®.

OUR SERVICES

Industry-leading iPSC Services

Ncardia provides its customers with a broad portfolio of cardiovascular iPSC services for safety and efficacy testing and analysis. The safety services are pre-configured service packages based on electrophysiology, biochemistry and contraction assay technology for predictive safety pharmacology and toxicology testing. Efficacy services range from disease modeling to cardiovascular drug efficacy screening.

SUPPORT

We are ready to help

Ncardia is committed to delivering to its clients working assay solutions, through in-house assay development and customized support. By combining our deep portfolio of differentiated cardiac and neuronal iPSC cell products with our well-equipped laboratories, we provide scientists with top quality support for almost every application. The company has freely available application scientists knowledgeable in areas including but not limited to electrophysiology-, biochemistry- and contraction-based assays for predictive safety pharmacology and toxicology testing. Do not hesitate to talk to our experts today!